| IMUNON INC. NEW DL-,01 |
| USA |
| Gesundheit |
| US15117N7012 / A41CNR |
| CBO0 (Frankfurt) / IMNN (NASDAQ) |
| FRA:CBO0, ETR:CBO0, CBO0:GR, NASDAQ:IMNN |
| - |
| https://imunon.com/ |
|
Imunon, Inc. is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies and DNA-based vaccines aimed at treating challenging diseases. The company's leading program, ..
>Volltext.. |
| 8.73 Mio. EUR |
| 5.19 Mio. EUR |
| - |
| -11.93 Mio. EUR |
| -12.35 Mio. EUR |
| -8.92 EUR |
| 0.95 Mio. EUR |
| 4.52 Mio. EUR |
| -12.63 Mio. EUR |
| 1.25 |
| - |
| 30.1% |
| - |
| - |
| - |
| - |
| IMUNON |
| 25.03.26 |
|